BMY · Bristol-Myers Squibb Co.

Current Thesis

Bristol Myers Squibb’s growth-drug replacement story needs renewed price confirmation: the case requires a daily close above the September 18 reference high of $68.09 before a daily close below $63 breaks the published structure. The fundamental anchor remains the July 30 increase in FY2026 revenue guidance to $49–50 billion and adjusted earnings per share to $6.75–7.00. Those are management forecasts, not realized results. July 30 earnings release filed with the SEC.

Since the September 6 assessment, Bristol Myers has announced positive arlocabtagene autoleucel results on September 8 and Sotyktu extension data on September 17. Yet the supplied adjusted close was $63.06 on September 18, compared with $66.82 on September 4. The narrative is maturing — the July guidance reset has acquired further clinical evidence, but the September 18 price observation does not establish renewed upward momentum. This is an inference from the dated announcements and closes, not a measurement of investor flows.

Bullish and bearish views on Bristol-Myers Squibb Co.

The model's bull view on Bristol-Myers Squibb Co. (BMY), in brief: The earnings reset remains substantive. On July 30, 2026, Bristol Myers reported second-quarter revenue of $12.973 billion and adjusted earnings of $2.04 per share, against supplied consensus estimates of $11.745 billion and $1.59. The raised annual guidance provides a concrete… The bear view: Price confirmation has weakened. The September 18, 2026 adjusted close of $63.06 sits near the $63 thesis threshold published on September 6. Positive September clinical announcements have therefore coincided with a lower reference close than September 4; the observations do not… Both cases follow in full.

Bull Case

• The earnings reset remains substantive. On July 30, 2026, Bristol Myers reported second-quarter revenue of $12.973 billion and adjusted earnings of $2.04 per share, against supplied consensus estimates of $11.745 billion and $1.59. The raised annual guidance provides a concrete test at the next results announcement; a reduction would contradict the durability argument.
• Arlo-cel adds fresh pipeline evidence. On September 8, 2026, Bristol Myers said QUINTESSENTIAL met its primary overall-response endpoint and key complete-response endpoint in heavily pretreated multiple myeloma. The announcement supplied neither numerical response rates nor a dated regulatory submission, limiting conclusions about commercial contribution. Company announcement.
• Sotyktu shows sustained clinical responses. In the September 17, 2026 POETYK PsA-2 disclosure, continuously treated extension participants had a week-104 minimal-disease-activity response of 51.2% using observed data and 43.7% when missing observations counted as nonresponses. These results support durability among extension participants; they do not establish future prescription growth. Company data release.

Bear Case

• Price confirmation has weakened. The September 18, 2026 adjusted close of $63.06 sits near the $63 thesis threshold published on September 6. Positive September clinical announcements have therefore coincided with a lower reference close than September 4; the observations do not establish what caused the decline.
• Extension results have selection limits. The September 17, 2026 Sotyktu release says 245 of the 312 participants originally assigned continuous treatment entered the optional extension. That selection and the difference between observed and missing-data-adjusted responses limit extrapolation to every patient starting treatment.
• The autoimmune safety question remains separate. BioPharma Dive’s August 31, 2026 report attributed a voluntary zola-cel enrollment pause to a company spokesperson following inflammatory events. The September 8 arlo-cel announcement concerns a different candidate and disease setting; it does not establish resolution of that pause.

Setup & Price Structure

The supplied September 18, 2026 adjusted series records a $63.06 close, a $68.09 trailing-year high, a 7.4% distance below that high and a three-month price increase of 16.6%. Its 14-day relative strength index was 27.7. These measurements describe a positive three-month change alongside weak recent momentum; they do not establish that a rebound has begun.

The $63 level is the research threshold retained from the September 6 publication, not a newly verified moving average or volume-supported shelf. A daily close above $68.09 before a daily close below $63 defines successful price confirmation for this dossier. The low-conviction forecast reflects the September 18 close’s proximity to invalidation despite the positive clinical updates.

Crowding cannot be established from the available evidence. The September 18 headline about health-care options activity provides no BMY-specific direction or magnitude, while moving-average distances, fund flows and current insider transactions are absent. The observable event concentration is the September 30 Camzyos regulatory date; it is not evidence of crowded ownership.

Catalyst Calendar (next 30 days)

• 2026-09-30 — Camzyos adolescent decision. Bristol Myers’ June 1, 2026 announcement identifies this as the Food and Drug Administration’s Prescription Drug User Fee Act (PDUFA) target action date for the adolescent application. Approval would resolve the label-extension question; a refusal or extension would defeat the dated approval leg without independently disproving the annual revenue outlook. Company regulatory announcement.
• ~2026-10-29, estimated — Third-quarter results. This date remains the calendar estimate cited in the September 6 publication, not a company-confirmed date. Outside the next 30 days, the report is the decisive fundamental check on the July 30 FY2026 revenue range of $49–50 billion and adjusted earnings range of $6.75–7.00 per share.

What Would Change Our Mind

Loss of the published July-reset structure ends this price thesis: a daily close below $63 is the observable condition, retained from September 6. The September 18 close of $63.06 is above that threshold; this observation alone does not establish whether every intervening session also remained above it.

A daily close above the September 18 reference high of $68.09 before the downside condition occurs would establish that the price case played out. Fundamentally, a reduction to the July 30 annual guidance would contradict the earnings-replacement argument. A September 30 Camzyos refusal or announced deadline extension would separately invalidate the expected timing of that regulatory contribution.

Correlation Notes

This is a single-company replacement-growth thesis anchored in Bristol Myers’ July 30 guidance and September clinical disclosures. No paired benchmark-return series accompanies the September 18 price observations, so a numerical correlation with pharmaceutical equities or attribution of the decline to sector flows is unsupported.

The August 31 zola-cel pause and September 8 arlo-cel results also concern different investigational therapies. Their coexistence supports neither a blanket recovery nor a blanket failure across the company’s chimeric antigen receptor (CAR) T-cell programs; candidate-specific safety and efficacy disclosures remain the relevant evidence.